|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:27212383 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression multiple interactions |
EXP |
Vitamin K 2 results in increased expression of ALPL protein PTH protein promotes the reaction [Vitamin K 2 results in increased expression of ALPL protein]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of ALPL protein] |
CTD |
PMID:30639440 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Axl |
Axl receptor tyrosine kinase |
multiple interactions |
EXP |
Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein] |
CTD |
PMID:27212383 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein] |
CTD |
PMID:27212383 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases secretion decreases expression |
ISO EXP |
Vitamin K 2 inhibits the reaction [IL1B protein results in decreased expression of BGLAP protein modified form] PTH protein promotes the reaction [Vitamin K 2 results in increased carboxylation of BGLAP protein]; PTH protein promotes the reaction [Vitamin K 2 results in increased secretion of BGLAP protein modified form]; Vitamin K 2 promotes the reaction [PTH protein results in increased carboxylation of BGLAP protein]; Vitamin K 2 promotes the reaction [PTH protein results in increased secretion of BGLAP protein modified form]; Vitamin K 2 results in increased carboxylation of and results in decreased secretion of BGLAP protein Vitamin K 2 results in decreased expression of BGLAP mRNA |
CTD |
PMID:19675304 PMID:20460758 PMID:30639440 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Vitamin K 2 results in decreased expression of BIRC5 protein |
CTD |
PMID:29432837 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Vitamin K 2 affects the reaction [PTH protein results in increased expression of BMP2 protein] |
CTD |
PMID:30639440 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
[Vitamin K 2 co-treated with arsenic trioxide] results in increased expression of CASP3; Acetylcysteine inhibits the reaction [[Vitamin K 2 co-treated with arsenic trioxide] results in increased expression of CASP3] Vitamin K 2 results in increased cleavage of CASP3 protein |
CTD |
PMID:24273890 PMID:29432837 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases cleavage |
ISO |
Vitamin K 2 results in increased cleavage of CASP7 protein |
CTD |
PMID:29432837 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Vitamin K 2 results in decreased expression of CDK4 mRNA |
CTD |
PMID:16010434 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Vitamin K 2 results in increased expression of CDKN1A protein |
CTD |
PMID:29432837 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Vitamin K 2 results in increased expression of CDKN2A mRNA |
CTD |
PMID:16010434 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
Vitamin K 2 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:19675304 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
EXP |
[Phenobarbital co-treated with Vitamin K 2] results in increased activity of F10 protein |
CTD |
PMID:19952496 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F7 |
coagulation factor VII |
multiple interactions |
EXP |
[Phenobarbital co-treated with Vitamin K 2] results in increased activity of F7 protein |
CTD |
PMID:19952496 |
|
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
|
|
G |
Gas6 |
growth arrest specific 6 |
multiple interactions |
EXP |
Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein] |
CTD |
PMID:27212383 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Vitamin K 2 results in increased phosphorylation of H2AX protein |
CTD |
PMID:29432837 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Vitamin K 2 results in decreased expression of HSPA5 protein |
CTD |
PMID:29432837 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases response to substance |
ISO |
Vitamin K 2 inhibits the reaction [IL1B protein results in decreased expression of BGLAP protein modified form]; Warfarin inhibits the reaction [Vitamin K 2 results in decreased susceptibility to IL1B protein] |
CTD |
PMID:20460758 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
PROX1 protein inhibits the reaction [Vitamin K 2 results in increased activity of NR1I2 protein] |
CTD |
PMID:22023334 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Vitamin K 2 results in increased cleavage of PARP1 protein |
CTD |
PMID:29432837 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Prox1 |
prospero homeobox 1 |
multiple interactions |
ISO |
PROX1 protein inhibits the reaction [Vitamin K 2 results in increased activity of NR1I2 protein] |
CTD |
PMID:22023334 |
|
NCBI chr13:101,669,184...101,719,804
Ensembl chr13:101,669,184...101,711,183
|
|
G |
Pth |
parathyroid hormone |
multiple interactions |
EXP |
PTH protein promotes the reaction [Vitamin K 2 results in increased carboxylation of BGLAP protein]; PTH protein promotes the reaction [Vitamin K 2 results in increased expression of ALPL protein]; PTH protein promotes the reaction [Vitamin K 2 results in increased expression of RUNX2 protein]; PTH protein promotes the reaction [Vitamin K 2 results in increased expression of SP7 protein]; PTH protein promotes the reaction [Vitamin K 2 results in increased secretion of BGLAP protein modified form]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of ALPL protein]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of BMP2 protein]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of RUNX2 protein]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of SP7 protein]; Vitamin K 2 promotes the reaction [PTH protein results in increased carboxylation of BGLAP protein]; Vitamin K 2 promotes the reaction [PTH protein results in increased secretion of BGLAP protein modified form] |
CTD |
PMID:30639440 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases expression |
ISO |
Vitamin K 2 results in increased expression of RB1 mRNA |
CTD |
PMID:16010434 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
EXP |
Vitamin K 2 results in increased expression of RUNX2 protein PTH protein promotes the reaction [Vitamin K 2 results in increased expression of RUNX2 protein]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of RUNX2 protein] |
CTD |
PMID:30639440 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions decreases phosphorylation |
ISO |
[Vitamin K 2 co-treated with 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid] results in decreased phosphorylation of RXRA protein Vitamin K 2 results in decreased phosphorylation of RXRA protein |
CTD |
PMID:17270033 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression multiple interactions |
EXP |
Vitamin K 2 results in increased expression of SP7 protein PTH protein promotes the reaction [Vitamin K 2 results in increased expression of SP7 protein]; Vitamin K 2 affects the reaction [PTH protein results in increased expression of SP7 protein] |
CTD |
PMID:30639440 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Vitamin K 2 results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:19675304 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases activity |
ISO |
menatetrenone results in increased activity of ALPL protein |
CTD |
PMID:11113387 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions increases carboxylation |
ISO |
menatetrenone results in increased expression of BGLAP mRNA Warfarin inhibits the reaction [menatetrenone results in increased carboxylation of BGLAP protein] |
CTD |
PMID:11113387 PMID:31173816 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression increases response to substance |
ISO |
Coumestrol inhibits the reaction [menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]]; Coumestrol inhibits the reaction [menatetrenone results in increased expression of BMP2 mRNA]; Coumestrol inhibits the reaction [menatetrenone results in increased susceptibility to BMP2 protein]; Coumestrol inhibits the reaction [Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA]]; Ketoconazole inhibits the reaction [menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]]; Ketoconazole inhibits the reaction [Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA]]; menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]; Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA] |
CTD |
PMID:31843813 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
menatetrenone results in increased activity of NR1I2 protein |
CTD |
PMID:31843813 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
menatetrenone results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:31173816 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
menatetrenone inhibits the reaction [Calcitriol results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:11113387 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Ubiad1 |
UbiA prenyltransferase domain containing 1 |
multiple interactions |
ISO |
[UBIAD1 protein results in increased metabolism of Vitamin K metabolite] which results in increased chemical synthesis of menatetrenone |
CTD |
PMID:20953171 |
|
NCBI chr 5:158,856,582...158,880,490
Ensembl chr 5:158,868,672...158,880,271
|
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases carboxylation |
ISO |
Warfarin inhibits the reaction [menaquinone 7 results in increased carboxylation of BGLAP protein] |
CTD |
PMID:31173816 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
menaquinone 7 results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:31173816 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|